Conditions: Neoplasms, Breast
Keywords: lapatinib advanced metastatic breast cancer GW572016 ErbB2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 138
Healthy volunteers: no

Brief summary:
This phase II study will evaluate and compare the efficacy and tolerability of two dose schedules (1500 mg QD and 500 mg BID) of oral Lapatinib as treatment for patients with advanced or metastatic breast cancer.

Detailed description:

Arms:

Interventions: intervention 1: Lapatinib
Intervention descriptions: intervention 1: None

Protocol document: